9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
• 英文别名: [9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
• 化学式: C₂₇H₃₀Cl₂O₆
• 分子量: 521.4
• InChiKey: WOFMFGQZHJDGCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  93.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same
  申请人：Laboratory Skin Care, Inc.

  公开号：US10758478B2

  公开（公告）日：2020-09-01

  Uniform, rigid, spherical nanoporous calcium phosphate particles that define an internal space and an amount of active agent present in the internal space are provided. Also provided are topical delivery compositions that include the active agent loaded particles, as well as methods of making the particles and topical compositions. The particles and compositions thereof find use in a variety of different applications, including active agent delivery applications.

  本发明提供了均匀、坚硬、球形的纳米多孔磷酸钙颗粒，这些颗粒限定了内部空间和内部空间中的活性剂含量。此外，还提供了包括活性剂负载颗粒的局部给药组合物，以及制造颗粒和局部组合物的方法。这些颗粒及其组合物可用于各种不同的应用，包括活性剂递送应用。
• Oligomer-Corticosteroid Conjugates
  申请人：Zhang Wen

  公开号：US20100286107A1

  公开（公告）日：2010-11-11

  The invention provides corticosteroids that are chemically modified by covalent attachment of a water soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water soluble oligomer.
• OLIGOMER-CORTICOSTEROID CONJUGATES
  申请人：NAKTAR THERAPEUTICS

  公开号：US20140309398A1

  公开（公告）日：2014-10-16

  The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits different properties compared to the properties of the corticosteroid not attached to the water-soluble oligomer.
• US8796248B2
  申请人：——

  公开号：US8796248B2

  公开（公告）日：2014-08-05
• [EN] OLIGOMER-CORTICOSTEROID CONJUGATES<br/>[FR] CONJUGUÉS D'OLIGOMÈRES ET CORTICOSTÉROÏDES
  申请人：NEKTAR THERAPEUTICS AL CORP

  公开号：WO2009045539A2

  公开（公告）日：2009-04-09

  The invention provides corticosteroids that are chemically modified by covalent attachment of a water soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water soluble oligomer.